All In Biotech

Drug Trial Radar · NCT02705105

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

114

Actual

Start

Feb 2016

Primary completion

Aug 22, 2018

Study completion Oct 10, 2018

Sponsor

Lead sponsor
Kyowa Kirin, Inc.Industry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Mar 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.

Conditions

  • Solid Tumor
  • Cancer
  • Carcinoma
  • Hepatocellular Carcinoma
  • HCC

Interventions

  • Mogamulizumab + NivolumabBiological

    i.v. administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD)Time frame: From the first dose of study medications until 14 days after the last dose of study medication
  2. Number of Subjects Experiencing Dose-limiting ToxicityTime frame: From the first dose of study medications until 14 days after the last dose of study medication

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Gilbert, Arizona

  • Site not named

    Greenbrae, California

  • Site not named

    Los Angeles, California

  • Site not named

    Jacksonville, Florida

  • Site not named

    Augusta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Kalamazoo, Michigan

  • Site not named

    Piscataway, New Jersey

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Goldsboro, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.